As mentioned in the Introduction, there is accumulating evidence for differential EFA6R expression in malignant diseases such as ovarian cancer (7, 14, 19, –, 22), and experiments are now in progress to determine the role of EFA6R in ovarian cancer. Here, PSD3 is linked to ovarian carcinoma.